Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Ureter Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Ureter Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Ureter Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Triple-Negative Breast Cancer (TNBC)

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Epithelial Ovarian Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Epithelial Ovarian Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Peritoneal Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Peritoneal Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Urethral Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Urethral Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Urethral Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Gastric Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Gastric Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Metastatic Ovarian Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Pancreatic Ductal Adenocarcinoma

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Fallopian Tube Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Non-Small Cell Lung Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Endometrial Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Endometrial Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Small-Cell Lung Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Small-Cell Lung Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Bladder Cancer: Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Bladder Cancer

Data Insights

MHB-036C by Minghui Pharmaceutical (Shanghai) for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....

Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Esophageal Squamous Cell Carcinoma (ESCC)